Inhibikase Therapeutics, Inc. (IKT)
Nasdaq · Healthcare · Biotechnology
$2.000.00%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $279M
- 52-week range
- $1.33 – $2.61
- 52-week change
- +23.46%
- EPS (trailing)
- −$0.43
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Nov 13, 2026
Fiscal year to Dec 2025
- Net income
- −$48.3M
- Diluted EPS
- −$0.49
- Free cash flow
- −$27.8M
From the company’s annual report on SEC EDGAR.
About Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte.
Headquarters: Wilmington, United States · 35 employees · inhibikase.com